Goldman, Butterwick, Fitzpatrick and Groff
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Goldman, Butterwick, Fitzpatrick and Groff sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Goldman, Butterwick, Fitzpatrick and Groff: 18 sponsored US clinical trials, none currently recruiting.
Goldman, Butterwick, Fitzpatrick and Groff sponsors 18 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 5 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Volume Loss to Dorsum of Hands, with 1 trials.
Top-decile sponsor footprint
Goldman, Butterwick, Fitzpatrick and Groff ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Indexed trials (enrollment closed)
18 total, page 1 of 1
Analyze Previously Collected Biopsy Samples From Participants Who Completed the "SPLASH: Split-Body Randomized Clinical Trial of Poly-L-Lactic Acid for Adipogenesis and Volumization of the Hip Dell" Study
NCT06656923
Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms
NCT07686198
Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist
NCT07558603
Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines
NCT07421544
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
NCT07342413
Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists
NCT07221461
Assess Impact of Poly-L-lactic Acid on GLP1 Subjects
NCT07217743
Evaluate the Safety and Efficacy of a Topical Serum (AGE Serum) in Improving Visible Signs of Aging
NCT07216352
1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss
NCT06926023
Skin Care Regimen for Improving Photoaging Signs on the Face
NCT06603857
Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging
NCT04137263
Sculptra Aesthetic for the Treatment of Upper Knee Skin Laxity
NCT03487172
Kybella With Triamcinolone
NCT03361176
Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat
NCT03241563
TR-987 vs. Placebo Following Fractionated CO2 Laser Resurfacing of the Chest
NCT02681224
A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study of Injectable Calcium Hydroxylapatite With and Without Triamcinolone Acetate for the Treatment of Volume Loss to Dorsum Areas of the Hands
NCT02454088
A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy
NCT02451579
Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%
NCT02446223
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 4 | 5 |
Therapeutic Areas
How the Goldman, Butterwick, Fitzpatrick and Groff archive is shaped
18 indexed studies, none listed as recruiting (0% open); 8 completed (44%).
Phase mix: 5 late (III/IV) vs 4 early (I/II) (balanced across stages).
Top condition: Volume Loss to Dorsum of Hands (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Goldman, Butterwick, Fitzpatrick and Groff: archived-pipeline peers nationwide
Peers matched on 18 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Goldman, Butterwick, Fitzpatrick and Groff sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 archived trials
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Goldman, Butterwick, Fitzpatrick and Groff page
18 registered trials is a research-attention snapshot, not an endorsement of Goldman, Butterwick, Fitzpatrick and Groff or any single study.
- None of Goldman, Butterwick, Fitzpatrick and Groff's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Volume Loss to Dorsum of Hands is the condition Goldman, Butterwick, Fitzpatrick and Groff studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Volume Loss to Dorsum of Hands trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Goldman, Butterwick, Fitzpatrick and Groff pipeline card: 18 registered trials from official public datasets.Report a data error.